Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)

Inclusion Criteria: * signed informed consent * patients age 18 years and older * histologically confirmed adenocarcinoma of the rectum * intermediate risk rectal cancer or low risk distal rectal cancer Exclusion Criteria: * evidence of metastatic disease * prior radiation therapy for disease under study * prior treatment with CD137 agonists or immune checkpoint blockade therapies * current or recent use of acetylsalicylic acid * history of clinically significant cardiac or pulmonary dysfunction pregnancy or breastfeeding * significant auto-immune disease